Thursday, November 3, 2016

Tesaro Announces Submission of Niraparib NDA For Platinum-sensitive, Recurrent Ovarian Cancer

Treatment for Ovarian Cancer, Fallopian Tube Cancer, Peritoneal CancerTesaro Announces Submission of … germline BRCA mutation carriers (non-gBRCAmut), tumor samples were assessed for HRD … niraparib specifically for patients with prostate cancer worldwide, except in Japan.
In …

No comments:

Post a Comment